TOKYO, Mar 31 (Pulse News Wire) – Wolves Hand Co., Ltd. (194A.T) announced today that its clinical trial using fucosyllipid, derived from brown algae, showed promising results in treating canine melanoma.
The company began limited clinical studies in December 2025 as part of its cancer research project utilizing fucosyllipid, a metabolite of fucoxanthin. In case study one, involving a senior female small dog with oral melanoma, initial treatments with IR7,683-Lipo and hyperthermia therapy did not yield positive outcomes. However, after initiating intravenous administration of fucosyllipid, tumor growth was inhibited.
In case study two, a middle-aged female small dog also diagnosed with oral melanoma saw tumor regression approximately two weeks after beginning fucosyllipid treatment following surgical removal and subsequent recurrence despite supplementary mineral treatment. Fucosyllipid, known for its multifaceted biological effects, has garnered significant academic interest due to its potential role in various cellular mechanisms, including inflammation signaling pathways and cell survival processes. Wolves Hand's ongoing research aims to deepen understanding of fucosyllipid’s biological actions while scientifically evaluating its application in cancer treatment.
The company plans to continue rigorous clinical testing based on accumulated evidence and pursue innovative therapeutic development.
🟢 Confidence: High AI-translated content.